Laboratory assessment in musculoskeletal disorders

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 3, 2003, Pages 475-494

  Van Paassen, Pieter ^a   Damoiseaux, Jan ^a   Cohen Tervaert, Jan Willem ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoantibodies; Musculoskeletal disease

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA; IMMUNOGLOBULIN; INFLIXIMAB; ISONIAZID; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROCAINAMIDE; QUINIDINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIAGNOSTIC TEST; DRUG INDUCED DISEASE; HUMAN; IMMUNOASSAY; LABORATORY TEST; LUPUS VULGARIS; MUSCULOSKELETAL DISEASE; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCLEROSIS; SJOEGREN SYNDROME; STATISTICAL PARAMETERS; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOELECTROPHORESIS; PROGNOSIS; RADIOIMMUNOASSAY;

EID: 0038038915     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(03)00029-9     Document Type: Review

References (54)

1. Davidson A & Diamond B. Autoimmune diseases. New England Journal of Medicine 2001; 345: 340-350.
2. Børretzen M, Mellbye OJ, Thompson KM & Natvig JB. Rheumatoid factors. In Peter JB & Shoenfeld Y (eds) Autoantibodies. Amsterdam: Elsevier Science, 1996, pp 706-715.
3. Wener MH & Mannik M. Rheumatoid factors. In Rose NR, Conway de Macario E & Folds JD (eds) Manual of Clinical Laboratory Immunology. Washington, DC: ASM Press, 1997, pp 942-948.
4. Gorevic PD, Galanakis D & Finn AF. Cryoglobulins. In Rose NR, Conway de Macario E & Folds JD (eds) Manual of Clinical Laboratory Immunology. DC: ASM Press, 1997, pp 217-223.
5. Youinou P, Le Goff P & Maran R. Perinuclear factor (profilaggrin) autoantibodies. In Peter JB & Shoenfeld Y (eds) Autoantibodies. Amsterdam: Elsevier Science, 1996, pp 618-623.
6. Serre G & Vincent C. Filaggrin autoantibodies. In Peter JB & Shoenfeld Y (eds) Autoantibodies. Amsterdam: Elsevier Science, 1996, pp 271-276.
7. Schellekens GA, Visser H, De Jong BAW et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis & Rheumatism 2000; 43: 155-164.
8. Griesmacher A & Peichl P. Autoantibodies associated with rheumatic diseases. Clinical and Chemical Laboratory Medicine 2001; 39: 189-208.
9. Cohen Tervaert JW, Damoiseaux J, Boomsma MM & Stegeman CA. Absence of anti-cyclic citrullinated peptide antibodies in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism 2002; 246: 849-850.
10. Tan EM, Feltkamp TE, Smolen JS et al. Range of antinuclear antibodies in 'healthy individuals'. Arthritis & Rheumatism 1997; 40: 1601-1611.
11. Hollingworth PN, Pummer SC & Dawkins RL. Antinuclear antibodies. In Peter JB & Shoenfeld Y (eds) Autoantibodies. Amsterdam: Elsevier Science, 1996, pp 74-90.
12. Fritzler MJ & Miller BJ. Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using (3)21a transfected and overexpressed human 60 kDa Ro autoantigen in Hep-2 cells. Journal of Clinical Laboratory Analysis 1995; 9: 218-224.
13. Charles PJ, Smeenk RJ, De Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF-alpha. Arthritis & Rheumatism 2000; 43: 2383-2390.
14. Day R, Adverse reactions to TNF-alpha inhibition in rheumatoid arthritis. Lancet 2002; 359: 540-541.
15. Hahn BH. Antibodies to DNA. New England Journal of Medicine 1998; 338: 1359-1368.
16. Smeenk RJT, Berden JHM & Swaak AJG. DsDNA autoantibodies. In Peter JB & Shoenfeld Y (eds) Autoantibodies. Amsterdam: Elsevier Science, 1996, pp 227-236.
17. Van Venrooy WJ & Maini RN (eds) Manual of Biological Markers of Disease. Dordrecht: Kluwer Academic Publishers, 1996.
18. Bridges AJ, Lorden TE & Havighurst TC. Autoantibody testing for connective tissue diseases. Comparison of immunodiffusion, immunoblot and enzyme-immunoassay. American Journal of Clinical Pathology 1997; 108: 406-410.
19. Cohen Tervaert JW, Limburg PCC, Elema JD et al. Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. American Journal of Medicine 1991; 91: 59-66.
20. Davies DJ, Moran JE, Niall JF & Ryan GB. Segmenting necrotizing glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology? British Medical Journal (Clinical Research Edition) 1982; 285: 606.
21. Cohen Tervaert JW, Goldschmeding R, Elema JD et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney International 1990; 37: 799-806.
22. Westman KW & Selga D. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutropil cytoplasmic antibody. Kidney International 1998; 53: 1230-1236.
23. Csernok ED, Ahlquist D, Ullrich S & Gross WL. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase-3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangitis. Rheumatology 2002; 41: 1313-1317.
24. Boomsma MM, Stegeman CA, Oost-Kort WW et al. Native and recombinant proteins to analyze autoantibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. Journal of Immunological Methods 2001; 254: 47-58.
25. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association (ARA) revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 1988; 31: 315-324.
26. Pincus T, Breedveld FC & Emery P. Combination disease modifying antirheumatic therapy in rheumatoid arthritis. Clinical and Experimental Rheumatology 1999; 17(supplement): S1.
27. Smerling RH & Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity and predictive value. Archives of Internal Medicine 1992; 152: 2417-2420.
28. Teitsson L, Withrington RH, Seifer MH et al. Prospective study of early rheumatoid arthritis I. Prognostic value of IgA rheumatoid factor. Annals of the Rheumatic Diseases 1984; 43: 673-678.
29. Withrington RH, Teitsson L, Valdimarsson H et al. Prospective study of early rheumatoid arthritis II. Association of the rheumatoid factor isotypes with disease activity. Annals of the Rheumatic Diseases 1984; 43: 679-685.
30. Alleen C, Elson CJ, Scott DGI et al. IgG anti-globulins in rheumatoid arthritis and other arthritides: Relationship with clinical features and other parameters. Annals of the Rheumatic Diseases 1981; 40: 127-131.
31. Saraux A, Berthelot JM, Chales G et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis & Rheumatism 2002; 47: 155-165.
32. Visser H, Le Cessie S, Vos K et al. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis & Rheumatism 2002; 46: 357-362.
33. Manthorpe R, Jacobsson LT, Lirkava Z & Theander E. Epidemiology of Sjögren syndrome, especially its primary form. Annals Medicine Interne (Paris) 1998; 149: 7-11.
34. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis & Rheumatism 1993; 36: 340-347.
35. Fessel WJ. Systemic lupus erythematodes in the community. Incidence, prevalence, outcome, and first symptoms. Archives of Internal Medicine 1974; 134: 1027-1035.
36. Solomon DH, Kavanaugh HJ & Schur PH. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis & Rheumatism 2002; 47: 434-444.
37. Ter Borg EJ, Horst G, Hummel EJ et al. Measurement of increases in anti-double stranded DNA antibody levels of a predictor of disease exacerbation in SLE: A long term prospective study. Archives of Rheumatology 1990; 33: 634-643.
38. Bootsma H, Spronk PE, Ter Borg EJ et al. The predictive value of fluctuations in IgM and IgG class anti dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Annals of the Rheumatic Diseases 1997; 56: 661-666.
39. Hirohata S & Kosaka M. Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematodes. Lancet 1994; 343: 796.
40. Buyon JP & Winchester R. Congenital complete heart block. A human model of passively acquired autoimmune injury. Arthritis & Rheumatism 1990; 33: 609-614.
41. Fritzler MJ & Tan EM. Antibodies to histones in drug-induced and idiopathic lupus erythematosus. Journal of Clinical Investigation 1978; 62: 560-567.
42. Fremeaux-Bacchi V, Noël LH & Schifferli JA. No lupus nephritis in the absence of antic Ig autoantibodies? Nephrology Dialysis Transplantation 2002; 17: 2041-2043.
43. Tan EM, Rodnan GP, Garcia I et al. Diversity of antinuclear antibodies in progressive systemic sclerosis: Anticentromere antibody and its relationship to CREST syndrome. Arthritis & Rheumatism 1980; 23: 617-625.
44. Hoffman RW & Greidinger EL. Mixed connective tissue disease. Current Opinion in Rheumatology 2000; 12: 386-390.
45. Nimelstein SH, Brody S, McShane D & Holman HR. Mixed connective tissue disease: A subsequent evaluation of the original 25 patients. Medicine 1980; 59: 239-248.
46. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-374.
47. Miller FW, Waite KA, Biswas T & Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proceedings of the National Academy of Sciences of the USA 1990; 87: 9933-9937.
48. Leff RL, Burgess SH, Miller FW et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-I and anti-signal recognition particle autoantibodies. Arthritis & Rheumatism 1991; 34: 1391-1396.
49. Jennette J & Falk R. Small vessel vasculitis. New England Journal of Medicine 1997; 337: 1512-1523.
50. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. Journal of Clinical Investigation 2002; 110: 955-963.
51. Franssen CFM, Stegeman CA, Kallenberg CGM et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney International 2000; 57: 2195-2206.
52. Cohen Tervaert JW, Van Der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Archives of Internal Medicine 1989; 149: 2461-2465.
53. Boomsma MM, Stegeman CA, Van Der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis & Rheumatism 2000; 43: 2025-2033.
54. Franssen CF, Stegeman CA, Oost-Kort WW et al. Determinants of renal outcome in antimyeloperoxidase-associated necrotizing crescentic glomerulonephritis. Journal of the American Society of Nephrology 1998; 9: 1915-1923.